FDA single-use stance "hits OEMs, threatens patient safety"
This article was originally published in Clinica
Executive Summary
AdvaMed has challenged the FDA's decision to extend the deadline before third-party reprocessors must provide complete validation data to continue marketing certain risky reprocessed single-use devices (SUDs).